

CLAIMS

What is claimed is:

~~1. A method for administering a composition comprising an antibody that binds to human Siglec-8 to an individual in need thereof, the method comprising:~~

~~— administering a corticosteroid to the individual; and~~

~~at least 6 hours after administering the corticosteroid, administering to the individual a first dose of the composition.~~

~~2.1. Use of A method for administering a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for administration to an individual in need thereof, the method comprising wherein:~~

~~— administering to the individual a first dose of the composition;~~

~~wherein a corticosteroid is to be administered to the individual at least 6 hours prior to administration of the a first dose of the composition.~~

~~3.2. Use of A method for administering a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for administration to an individual in need thereof, the method comprising administering to the individual a first dose of the composition, wherein the a first dose of the composition is to be administered to the individual by intravenous infusion over a period of about 4 hours; wherein optionally a corticosteroid is to be administered to the individual at least 6 hours prior to administration of the first dose of the composition.~~

~~4. The method of claim 3, further comprising administering a corticosteroid to the individual at least 6 hours prior to administration of the first dose.~~

~~5.3. The method use of any one of claims 1, 2, and 4 or claim 2, wherein the corticosteroid is to be administered to the individual at least 12 hours and/or within 24 hours prior to administration of the first dose.~~

~~6. The method of any one of claims 1, 2, 4, and 5, wherein the corticosteroid is administered to the individual within 24 hours prior to administration of the first dose.~~

~~7.4.~~ The ~~method-use~~ of any one of claims ~~1, 2, and 4-6-3~~, wherein the corticosteroid is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone; and wherein optionally:

(a) 80mg or greater than 0.5mg/kg prednisone is to be administered to the individual at least 6 hours prior to administration of the first dose; or

(b) 80mg prednisone is to be administered to the individual at least 12 hours and less than 24 hours prior to administration of the first dose.

~~8. The method of claim 7, wherein 80mg or greater than 0.5mg/kg prednisone is administered to the individual at least 6 hours prior to administration of the first dose.~~

~~9. The method of claim 7, wherein 80mg prednisone is administered to the individual at least 12 hours and less than 24 hours prior to administration of the first dose.~~

~~10.5.~~ The ~~method-use~~ of any one of claims ~~1, 2, and 4-9-4~~, wherein the corticosteroid is to be self-administered by the individual; or wherein the corticosteroid is to be administered orally to the individual.

~~11. The method of any one of claims 1, 2, and 4-10, wherein the corticosteroid is administered orally to the individual.~~

~~12. The method of claim 1 or claim 2, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours.~~

~~13.6.~~ The ~~method-use~~ of any one of claims ~~23-512~~, wherein less than 50% of total volume of the first dose is to be administered to the individual in the first 2 hours of the infusion; wherein optionally:

(a) less than 30% of total volume of the first dose is to be administered to the individual in the first 2 hours of the infusion; and/or

(b) the first dose is to be administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15

minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes.

~~14. The method of claim 13, wherein less than 30% of total volume of the first dose is administered to the individual in the first 2 hours of the infusion.~~

~~15. The method of claim 13 or claim 14, wherein the first dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes.~~

~~16.7. The method use of any one of claims 1-615, wherein the antibody that binds to human Siglec-8 is to be administered to the individual at between 0.1mg/kg and 10mg/kg, at between about 1mg/kg and about 3mg/kg, at 1mg/kg, or at 3mg/kg in the first dose.~~

~~17. The method of claim 16, wherein the antibody that binds to human Siglec-8 is administered to the individual at between about 1mg/kg and about 3mg/kg in the first dose.~~

~~18. The method of claim 16, wherein the antibody that binds to human Siglec-8 is administered to the individual at 1mg/kg or 3mg/kg in the first dose.~~

~~19.8. The method use of any one of claims 1, 2, and 4-18-7, wherein:~~

~~(a) administration of the corticosteroid at least 6 hours prior to administration of the first dose reduces the risk of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose without administration of the corticosteroid at least 6 hours prior; or~~

~~(b) administration of the corticosteroid at least 6 hours prior to administration of the first dose reduces the severity of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose without administration of the corticosteroid at least 6 hours prior.~~

~~20. The method of any one of claims 1, 2, and 4-18, wherein administration of the corticosteroid at least 6 hours prior to administration of the first dose reduces the severity of~~

~~infusion-related reaction (IRR) in the individual, as compared to administration of the first dose without administration of the corticosteroid at least 6 hours prior.~~

~~21.9. The method-use of any one of claims 23-820, wherein:~~

~~(a) administration of the first dose of the composition by intravenous infusion over a period of about 4 hours reduces the risk of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose by intravenous infusion over a period that is less than about 4 hours; and/or~~

~~(b) administration of the first dose of the composition by intravenous infusion over a period of about 4 hours reduces the severity of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose by intravenous infusion over a period that is less than about 4 hours.~~

~~22. The method of any one of claims 3-21, wherein administration of the first dose of the composition by intravenous infusion over a period of about 4 hours reduces the severity of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose by intravenous infusion over a period that is less than about 4 hours.~~

~~23.10. The method-use of any one of claims 1-922, further comprising administering wherein a corticosteroid is to be administered to the individual 1-2 hours prior to administration of the first dose; and wherein optionally:~~

~~(a) the corticosteroid to be administered to the individual 1-2 hours prior to administration of the first dose is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone;~~

~~(b) 80mg or greater than 0.5mg/kg prednisone is to be administered to the individual 1-2 hours prior to administration of the first dose;~~

~~(c) the corticosteroid to be administered to the individual 1-2 hours prior to administration of the first dose is methylprednisolone; or~~

~~(d) 100mg methylprednisolone is to be administered to the individual 1-2 hours prior to administration of the first dose.~~

24. ~~—The method of claim 23, wherein the corticosteroid administered to the individual 1-2 hours prior to administration of the first dose is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone.~~

25. ~~—The method of claim 23 or claim 24, wherein 80mg or greater than 0.5mg/kg prednisone is administered to the individual 1-2 hours prior to administration of the first dose.~~

26. ~~—The method of claim 24, wherein the corticosteroid administered to the individual 1-2 hours prior to administration of the first dose is methylprednisolone.~~

27. ~~—The method of claim 23 or claim 26, wherein 100mg methylprednisolone is administered to the individual 1-2 hours prior to administration of the first dose.~~

28.11. The method use of any one of claims 1-1027, further comprising administering wherein an antihistamine is to be administered to the individual 1-2 hours prior to administration of the first dose; and wherein optionally:

(a) the antihistamine is cetirizine;

(b) 10mg cetirizine is to be administered to the individual 1-2 hours prior to administration of the first dose, or 40 minutes to 180 minutes prior to administration of the first dose; and/or

(c) the antihistamine is to be administered orally to the individual.

29. ~~—The method of claim 28, wherein the antihistamine is cetirizine.~~

30. ~~—The method of claim 29, wherein 10mg cetirizine is administered to the individual 1-2 hours prior to administration of the first dose.~~

31. ~~—The method of claim 29, wherein 10mg cetirizine is administered to the individual 40 minutes to 180 minutes prior to administration of the first dose.~~

32. ~~—The method of any one of claims 28-31, wherein the antihistamine is administered orally to the individual.~~

~~33.12.~~ The method-use of any one of claims 1-~~1132~~, ~~further comprising administering wherein~~ an antipyretic or non-steroidal anti-inflammatory drug (NSAID) is to be administered to the individual 1-2 hours prior to administration of the first dose; and wherein optionally:

(a) the antipyretic is acetaminophen;

(b) 975-1000mg acetaminophen is to be administered to the individual 1-2 hours prior to administration of the first dose, or no less than 40 minutes and no more than 180 minutes prior to administration of the first dose; or

(c) the antipyretic or NSAID is to be administered orally to the individual.

~~34.—The method of claim 33, wherein the antipyretic is acetaminophen.~~

~~35.—The method of claim 34, wherein 975-1000mg acetaminophen is administered to the individual 1-2 hours prior to administration of the first dose.~~

~~36.—The method of claim 34, wherein 975-1000mg acetaminophen is administered to the individual no less than 40 minutes and no more than 180 minutes prior to administration of the first dose.~~

~~37. The method of any one of claims 33-36, wherein the antipyretic or NSAID is administered orally to the individual.~~

~~38.13.~~ The method-use of any one of claims 1-~~1237~~, ~~further comprising administering to the individual wherein~~ a second dose of a composition comprising an antibody that binds to human Siglec-8 is to be administered to the individual, wherein the second dose is to be administered to the individual about 28 days or about 4 weeks after the first dose; and wherein optionally:

(a) the second dose is to be administered to the individual without administration of a corticosteroid to the individual 6-24 hours prior to administration of the second dose; or

(b) a corticosteroid is to be administered to the individual at least 6 hours prior to administration of the second dose.

~~39. The method of claim 38, wherein the second dose is administered to the individual without administration of a corticosteroid to the individual 6-24 hours prior to administration of the second dose.~~

~~40. The method of claim 38, wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the second dose.~~

~~41.14. The method-use of any one of claims 38-40~~claim 13, wherein the second dose of the composition is to be administered to the individual by intravenous infusion over a period of about 4 hours; and wherein optionally:

(a) less than 50% or less than 30% of total volume of the second dose is to be administered to the individual in the first 2 hours of the infusion; and/or

(b) the second dose is to be administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes.

~~42. The method of claim 41, wherein less than 50% of total volume of the second dose is administered to the individual in the first 2 hours of the infusion.~~

~~43. The method of claim 42, wherein less than 30% of total volume of the second dose is administered to the individual in the first 2 hours of the infusion.~~

~~44. The method of claim 42 or claim 43, wherein the second dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes.~~

~~45.15. The method-use of any one of claims 1338-1444~~, wherein the antibody that binds to human Siglec-8 is to be administered to the individual at between 0.1mg/kg and 10mg/kg in the second dose; and wherein optionally:

(a) the antibody that binds to human Siglec-8 is to be administered to the individual at between about 1mg/kg and about 3mg/kg, at 1mg/kg, or at 3mg/kg in the second dose; and/or

(b) the antibody that binds to human Siglec-8 is to be administered to the individual at 1mg/kg in the first dose and at 3mg/kg in the second dose.

~~46. The method of claim 45, wherein the antibody that binds to human Siglec-8 is administered to the individual at between about 1mg/kg and about 3mg/kg in the second dose.~~

~~47. The method of claim 45, wherein the antibody that binds to human Siglec-8 is administered to the individual at 1mg/kg or 3mg/kg in the second dose.~~

~~48. The method of claim 46 or claim 47, wherein the antibody that binds to human Siglec-8 is administered to the individual at 1mg/kg in the first dose and at 3mg/kg in the second dose.~~

~~49.16. The method-use of any one of claims 1338-1548, further comprising administeringwherein a corticosteroid is to be administered to the individual 1-2 hours prior to administration of the second dose; and wherein optionally:~~

~~(a) the corticosteroid to be administered to the individual 1-2 hours prior to administration of the second dose is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone; and/or~~

~~(b) 100mg methylprednisolone is to be administered to the individual 1-2 hours prior to administration of the second dose.~~

~~50. The method of claim 49, wherein the corticosteroid administered to the individual 1-2 hours prior to administration of the second dose is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone.~~

~~51. The method of claim 49 or claim 50, wherein 100mg methylprednisolone is administered to the individual 1-2 hours prior to administration of the second dose.~~

~~52.17. The method-use of any one of claims 1338-1651, further comprising administeringwherein an antihistamine is to be administered to the individual 1-2 hours prior to administration of the second dose; and wherein optionally:~~

(a) the antihistamine is cetirizine;

(b) 10mg cetirizine is to be administered to the individual 1-2 hours prior to administration of the second dose; and/or

(c) the antihistamine is to be administered orally to the individual.

~~53. The method of claim 52, wherein the antihistamine is cetirizine.~~

~~54. The method of claim 53, wherein 10mg cetirizine is administered to the individual 1-2 hours prior to administration of the second dose.~~

~~55. The method of any one of claims 52-54, wherein the antihistamine is administered orally to the individual.~~

~~56.18. The method-use of any one of claims 1338-1755, further comprising administering wherein an antipyretic or non-steroidal anti-inflammatory drug (NSAID) is to be administered to the individual 1-2 hours prior to administration of the second dose; and wherein optionally:~~

(a) the antipyretic is acetaminophen;

(b) 975-1000mg acetaminophen is to be administered to the individual 1-2 hours prior to administration of the second dose; and/or

(c) the antipyretic or NSAID is to be administered orally to the individual.

~~57. The method of claim 56, wherein the antipyretic is acetaminophen.~~

~~58. The method of claim 57, wherein 975-1000mg acetaminophen is administered to the individual 1-2 hours prior to administration of the second dose.~~

~~59. The method of any one of claims 56-58, wherein the antipyretic or NSAID is administered orally to the individual.~~

~~60.19. The method-use of any one of claims 1338-1859, further comprising administering to the individual wherein a third dose of a composition comprising an antibody that binds to human Siglec-8 is to be administered to the individual, wherein the third dose is to be administered to~~

the individual about 28 days or about 4 weeks after the second dose; and wherein optionally:

(a) the third dose is to be administered to the individual without administration of a corticosteroid to the individual 6-24 hours prior to administration of the third dose; or

(b) a corticosteroid is to be administered to the individual at least 6 hours prior to administration of the third dose.

~~61. The method of claim 60, wherein the third dose is administered to the individual without administration of a corticosteroid to the individual 6-24 hours prior to administration of the third dose.~~

~~62. The method of claim 60, wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the third dose.~~

~~63.20.~~ The ~~method-use~~ of ~~any one of claims 60-62~~claim 19, wherein the third dose of the composition is to be administered to the individual by intravenous infusion over a period of about 2 hours to about 4 hours.

~~64.21.~~ The ~~method-use~~ of claim ~~63~~20, wherein the third dose of the composition is to be administered to the individual by intravenous infusion:

(a) -over a period of about 2 hours, wherein optionally the third dose is to be administered to the individual by intravenous infusion according to the following schedule, in chronological order: 10 mL/hour for 30 minutes, 25 mL/hour for 15 minutes, 40 mL/hour for 15 minutes, 55 mL/hour for 15 minutes, 70 mL/hour for 15 minutes, 85 mL/hour for 15 minutes, and 100 mL/hour for 16 minutes;

(b) over a period of about 3 hours, wherein optionally the third dose is to be administered to the individual by intravenous infusion according to the following schedule, in chronological order: 2 mL/hour for 30 minutes, 10 mL/hour for 30 minutes, 20 mL/hour for 30 minutes, 40 mL/hour for 30 minutes, and 60 mL/hour for 64 minutes;

(c) over a period of about 4 hours, wherein optionally the third dose is to be administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour

for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes; or

(d) over a period of about 1 hour, wherein optionally the third dose is to be administered to the individual by intravenous infusion according to the following schedule, in chronological order: 24 mL/hour for 15 minutes, and 125.3 mL/hour for 45 minutes.

~~65.—The method of claim 64, wherein the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 10 mL/hour for 30 minutes, 25 mL/hour for 15 minutes, 40 mL/hour for 15 minutes, 55 mL/hour for 15 minutes, 70 mL/hour for 15 minutes, 85 mL/hour for 15 minutes, and 100 mL/hour for 16 minutes.~~

~~66.—The method of claim 63, wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 3 hours.~~

~~67.—The method of claim 66, wherein the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 2 mL/hour for 30 minutes, 10 mL/hour for 30 minutes, 20 mL/hour for 30 minutes, 40 mL/hour for 30 minutes, and 60 mL/hour for 64 minutes.~~

~~68.—The method of claim 63, wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours.~~

~~69.—The method of claim 68, wherein the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes.~~

~~70.—The method of any one of claims 60–62, wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 hour.~~

~~71.—The method of claim 70, wherein the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 24 mL/hour for 15 minutes, and 125.3 mL/hour for 45 minutes.~~

~~72.22.~~ The ~~method-use~~ of any one of claims 1-~~2160~~, wherein ~~the method comprises~~:

~~administering to the individual~~ a first dose of the composition is to be administered to the individual on Day 1, wherein the first dose of the composition is to be administered to the individual by intravenous infusion over a period of about 4 hours;

~~administering to the individual~~ a second dose of the composition is to be administered to the individual on Day 29, wherein the second dose of the composition is to be administered to the individual by intravenous infusion over a period of about 4 hours;
and

~~administering to the individual~~ a third dose of the composition is to be administered to the individual on Day 57, wherein the third dose of the composition is to be administered to the individual by intravenous infusion over a period of about 1 to about 4 hours;

wherein optionally a corticosteroid is to be administered to the individual at least 6 hours prior to administration of the first dose.

~~73. The method of claim 72, further comprising administering a corticosteroid to the individual at least 6 hours prior to administration of the first dose.~~

~~74.23.~~ The ~~method-use~~ of any one of claims 1-~~2273~~, wherein:

(a) ~~the individual has or has been diagnosed with a disease or disorder characterized by one or more of: an increase in activated eosinophils, increased activity of mast cells expressing Siglec-8, an increase in eosinophils and/or mast cells, or increased activation of eosinophils and/or mast cells;~~ or

(b) the individual has or has been diagnosed with a disease or disorder selected from the group consisting of: chronic rhinosinusitis with concomitant asthma, aspirin-exacerbated respiratory disease, adult onset non-atopic asthma with sinus disease, chronic obstructive pulmonary disease, fibrotic disease, pre-fibrotic disease, advanced systemic mastocytosis, indolent systemic mastocytosis (ISM), inflammatory bowel disease (IBD), eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), eosinophilic colitis (EOC), eosinophilic duodenitis, mast cell gastritis or mast cell gastroenteritis, gastritis or gastroenteritis with elevated mast cells, irritable bowel

syndrome with elevated mast cells, functional gastrointestinal disease, allergic conjunctivitis, giant papillary conjunctivitis, chronic urticaria, allergic bronchopulmonary aspergillosis (ABPA), allergic asthma, asthma with eosinophil or mast cell phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), celiac disease, gastroparesis, hypereosinophilic syndrome, atopic dermatitis, anaphylaxis, angioedema, mast cell activation syndrome/disorder, and eosinophilic fasciitis.

75. ~~The method of any one of claims 1-73, wherein the individual has or has been diagnosed with a disease or disorder selected from the group consisting of: chronic rhinosinusitis with concomitant asthma, aspirin-exacerbated respiratory disease, adult-onset non-atopic asthma with sinus disease, chronic obstructive pulmonary disease, fibrotic disease, pre-fibrotic disease, advanced systemic mastocytosis, indolent systemic mastocytosis (ISM), inflammatory bowel disease (IBD), eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), eosinophilic colitis (EOC), eosinophilic duodenitis, mast cell gastritis or mast cell gastroenteritis, gastritis or gastroenteritis with elevated mast cells, irritable bowel syndrome with elevated mast cells, functional gastrointestinal disease, allergic conjunctivitis, giant papillary conjunctivitis, chronic urticaria, allergic bronchopulmonary aspergillosis (ABPA), allergic asthma, asthma with eosinophil or mast cell phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), celiac disease, gastroparesis, hypereosinophilic syndrome, atopic dermatitis, anaphylaxis, angioedema, mast cell activation syndrome/disorder, and eosinophilic fasciitis.~~

76. ~~The method of any one of claims 1-73, wherein the method is used to treat an individual who has or has been diagnosed with a disease or disorder selected from the group consisting of: chronic rhinosinusitis with concomitant asthma, aspirin-exacerbated respiratory disease, adult-onset non-atopic asthma with sinus disease, chronic obstructive pulmonary disease, fibrotic disease, pre-fibrotic disease, advanced systemic mastocytosis, indolent systemic mastocytosis (ISM), inflammatory bowel disease (IBD), eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), eosinophilic colitis (EOC), eosinophilic duodenitis, mast cell gastritis or mast cell gastroenteritis, gastritis or gastroenteritis with elevated mast cells, irritable bowel syndrome with elevated mast cells, functional gastrointestinal disease, allergic conjunctivitis, giant papillary conjunctivitis, chronic urticaria, allergic bronchopulmonary aspergillosis (ABPA), allergic asthma, asthma with eosinophil or mast cell phenotype,~~

~~eosinophilic granulomatosis with polyangiitis (EGPA), celiac disease, gastroparesis, hypereosinophilic syndrome, atopic dermatitis, anaphylaxis, angioedema, mast cell activation syndrome/disorder, and eosinophilic fasciitis.~~

~~77.24.~~ The ~~method-use~~ of any one of claims 1-~~2376~~, wherein the antibody comprises a Fc region and N-glycoside-linked carbohydrate chains linked to the Fc region, wherein less than 50% of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue; and wherein optionally substantially none of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue.

~~78. The method of claim 77, wherein substantially none of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue.~~

~~79.25.~~ The ~~method-use~~ of any one of claims 1-~~2478~~, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein:

(a) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66;

(b) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71;

(c) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:6, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:16 or 21;

- (d) the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:11-14, and the light chain variable region comprises an amino acid sequence selected from SEQ ID NOs:23-24;
- (e) the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:2-14, and the light chain variable region comprises an amino acid sequence selected from SEQ ID NOs:16-24;
- (f) the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:2-10, and the light chain variable region comprises an amino acid sequence selected from SEQ ID NOs:16-22;
- (g) the heavy chain variable region comprises an HC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:26-29, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, an HC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:31-36, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, an HC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:38-43, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63, and an HC-FR4 comprising the amino acid sequence selected from SEQ ID NOs:45-46, and the light chain variable region comprises an LC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:48-49, an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, an LC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:51-53, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, an LC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:55-58, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66, and an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60;
- (h) the heavy chain variable region comprises an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63, and an HC-FR4 comprising the amino acid sequence of SEQ ID NO:45, and the light chain variable region comprises an LC-FR1 comprising the

amino acid sequence of SEQ ID NO:48, an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, an LC-FR3 comprising the amino acid sequence of SEQ ID NO:55, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66, and an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60;

(i) the heavy chain variable region comprises an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38, an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63, and an HC-FR4 comprising the amino acid sequence of SEQ ID NO:45, and the light chain variable region comprises an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48, an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, an LC-FR3 comprising the amino acid sequence of SEQ ID NO:58, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66, and an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60;

(j) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:88, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:91, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:94, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:97, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:103;

(k) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:89, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:92, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:95, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:98, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:104;

(l) the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:90, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:93, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:96, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:99, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:105;

(m) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:106, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:109;

(n) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:107, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:110; or

(o) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:108, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:111.

~~80. The method of any one of claims 1-78, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71.~~

~~81. The method of any one of claims 1-78, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NO:16 or 21.~~

~~82.26. The method use of any one of claims 1-2478, wherein:~~

(a) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:87; and/or a light chain comprising the amino acid sequence of SEQ ID NO:76;

(b) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:87; and a light chain comprising the amino acid sequence of SEQ ID NO:77;

(c) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:75; and a light chain comprising the amino acid sequence of SEQ ID NO:76 or 77;
or

(d) the antibody is lirentelimab.

~~83. The method of any one of claims 1-78, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:87; and/or a light chain comprising the amino acid sequence of SEQ ID NO:77.~~

~~84. The method of any one of claims 1-78, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:11-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:23-24.~~

~~85. The method of any one of claims 1-78, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:2-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:16-24.~~

~~86. The method of any one of claims 1-78, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:2-10; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:16-22.~~

~~87. The method of any one of claims 1-78, wherein the antibody comprises:~~

~~(a) heavy chain variable region comprising:~~

~~_____ (1) an HC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:26-29;~~

~~_____ (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61;~~

~~_____ (3) an HC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:31-36;~~

~~_____ (4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62;~~

~~_____ (5) an HC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:38-43;~~

~~_____ (6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and~~

~~_____ (7) an HC-FR4 comprising the amino acid sequence selected from SEQ ID NOs:45-46, and/or~~

~~_____ (b) a light chain variable region comprising:~~

~~_____ (1) an LC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:48-49;~~

~~_____ (2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64;~~

~~_____ (3) an LC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:51-53;~~

~~_____ (4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65;~~

~~_____ (5) an LC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:55-58;~~

~~_____ (6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and~~

~~_____ (7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60.~~

~~88. The method of any one of claims 1-78, wherein the antibody comprises:~~

~~(a) heavy chain variable region comprising:~~

- ~~————— (1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26;~~
- ~~————— (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61;~~
- ~~————— (3) an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34;~~
- ~~————— (4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62;~~
- ~~————— (5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38;~~
- ~~————— (6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and~~
- ~~————— (7) an HC-FR4 comprising the amino acid sequence of SEQ ID NOs:45; and/or~~

~~(b) a light chain variable region comprising:~~

- ~~————— (1) an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48;~~
- ~~————— (2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64;~~
- ~~————— (3) an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51;~~
- ~~————— (4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65;~~
- ~~————— (5) an LC-FR3 comprising the amino acid sequence of SEQ ID NO:55;~~
- ~~————— (6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and~~
- ~~————— (7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60.~~

89. The method of any one of claims 1-78, wherein the antibody comprises:

~~(a) heavy chain variable region comprising:~~

- ~~————— (1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26;~~
- ~~————— (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61;~~
- ~~————— (3) an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34;~~

- ~~—————(4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62;~~
- ~~—————(5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38;~~
- ~~—————(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and~~
- ~~—————(7) an HC-FR4 comprising the amino acid sequence of SEQ ID NOs:45; and/or~~

~~(b) a light chain variable region comprising:~~

- ~~—————(1) an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48;~~
- ~~—————(2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64;~~
- ~~—————(3) an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51;~~
- ~~—————(4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65;~~
- ~~—————(5) an LC-FR3 comprising the amino acid sequence of SEQ ID NO:58;~~
- ~~—————(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and~~
- ~~—————(7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60.~~

90. The method of any one of claims 1-78, wherein the antibody comprises:

~~—————a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:88, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:91, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:94; and/or a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:97, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:103;~~

~~—————a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:89, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:92, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:95; and/or a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID~~

NO:98, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:101, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:104; or

~~— a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:90, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:93, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:96; and/or a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:99, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:105.~~

91. ~~The method of any one of claims 1-78, wherein the antibody comprises:~~

~~— a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:109;~~

~~— a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:107; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:110; or~~

~~— a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:108; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:111.~~

92.27. The ~~method-use~~ of any one of claims ~~2579-2691~~, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody; and/or wherein the antibody depletes blood eosinophils and inhibits mast cell activation.

93. ~~The method of any one of claims 79-92, wherein the antibody depletes blood eosinophils and inhibits mast cell activation.~~

94.28. The ~~method-use~~ of any one of claims ~~2579-2793~~, wherein the antibody comprises a heavy chain Fc region comprising a human IgG Fc region; and wherein optionally:

(a) the human IgG Fc region comprises a human IgG1 Fc region, which is optionally non-fucosylated; or

(b) the human IgG Fc region comprises a human IgG4 Fc region, which optionally comprises the amino acid substitution S228P, wherein the amino acid residues are numbered according to the EU index as in Kabat.

~~95. The method of claim 94, wherein the human IgG Fc region comprises a human IgG1 Fc region.~~

~~96. The method of claim 95, wherein the human IgG1 Fc region is non-fucosylated.~~

~~97. The method of claim 94, wherein the human IgG Fc region comprises a human IgG4 Fc region.~~

~~98. The method of claim 97, wherein the human IgG4 Fc region comprises the amino acid substitution S228P, wherein the amino acid residues are numbered according to the EU index as in Kabat.~~

~~99.29.~~ The ~~method-use~~ of any one of claims ~~2579-2893~~, wherein:

(a) -the antibody has been engineered to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity, and wherein optionally the antibody comprises at least one amino acid substitution in the Fc region that improves ADCC activity; and/or

(b) at least one or two of the heavy chains of the antibody is non-fucosylated.

~~100. The method of claim 99, wherein the antibody comprises at least one amino acid substitution in the Fc region that improves ADCC activity.~~

~~101. The method of any one of claims 79-93, wherein at least one or two of the heavy chains of the antibody is non-fucosylated.~~

~~102.30.~~ The ~~method-use~~ of any one of claims 1-~~29101~~, wherein the antibody is a monoclonal antibody.

~~103.31.~~ The ~~method-use~~ of any one of claims 1-~~30102~~, wherein the individual is a human.

~~104.32.~~ The ~~method-use~~ of any one of claims 1-~~31103~~, wherein the composition comprises the antibody and a pharmaceutically acceptable carrier.

105. ~~A kit comprising a medicament comprising a composition comprising an antibody that binds to human Siglec-8 and a package insert comprising instructions for administration of the medicament in an individual in need thereof according to any one of claims 1-104.~~